Activities of Anna ZÁBORSKÁ related to 2017/2254(INI)
Plenary speeches (1)
A European One Health Action Plan against Antimicrobial Resistance (A8-0257/2018 - Karin Kadenbach) SK
Shadow opinions (1)
OPINION on a European One Health Action Plan against Antimicrobial Resistance (AMR)
Amendments (15)
Amendment 9 #
Draft opinion
Recital A
Recital A
A. whereas antimicrobial resistance (AMR)-related challenges will increase in the years ahead and effective action is reliant on continued, cross-sectoral investments in research & innovation (R&I), so that better tools, products and approaches, also on long term, can be developed following a One Health approach;
Amendment 11 #
Draft opinion
Recital A a (new)
Recital A a (new)
Aa. whereas the political declaration endorsed by Heads of State at the United Nations General Assembly in New York in September 2016 signalled the world’s commitment to taking abroad, coordinated approach to address the root causes of antimicrobial resistance across multiple sectors;
Amendment 13 #
Draft opinion
Recital A a (new)
Recital A a (new)
Aa. whereas in the past 40 years only one novel class of antibiotics has been developed, despite the spreading and progress of new resistant bacteria, moreover there is clear evidence of resistance to new agents within existing classes of antibiotics;
Amendment 15 #
Draft opinion
Recital A b (new)
Recital A b (new)
Ab. whereas more than 100 companies have signed Davos declaration in January 2016, which calls for collective action to create a sustainable and predictable market for antibiotics, vaccines and diagnostics, that enhances conservation for new and existing treatments. It also calls for coordinated action to improve prevention of infections, hygiene, stewardship and conservation measures;
Amendment 16 #
Draft opinion
Recital A b (new)
Recital A b (new)
Ab. whereas awareness of prevention and of the misuse of antimicrobials is still low across Member States; and whereas vaccination is an effective way of preventing infections that would need treatment with antibacterials and thereby reducing development of resistance;
Amendment 17 #
Draft opinion
Recital A c (new)
Recital A c (new)
Ac. whereas nosocomial infections represents major threat in preserving and guarantee basic health care all over the world;
Amendment 19 #
Draft opinion
Recital B a (new)
Recital B a (new)
Ba. whereas antimicrobial resistance can only be effectively addressed on global level and with engagement of private sector;
Amendment 20 #
Draft opinion
Recital B b (new)
Recital B b (new)
Bb. whereas science and research play a crucial role in the development of standards in the fight against AMR;
Amendment 24 #
Draft opinion
Recital C a (new)
Recital C a (new)
Ca. whereas effective fight against AMR must be part of the broader international initiative with engaging as many international institutions, agencies and experts as possible;
Amendment 51 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Calls for the use of transferable market exclusivities as an option of meaningful incentives, which would allow the licensee of a new antimicrobial compound to extend to exclusivity of another compound, provided that they are applied with due consideration to the sustainability of healthcare systems;
Amendment 60 #
Draft opinion
Paragraph 3
Paragraph 3
3. Expresses the urgent need to foster partnerships throughout the EU in order to enhance the exchange of best practices and improve knowledge on AMR; encourages further pursuing private-public collaborations, such as the Innovative Medicine Initiative (IMI) programmes "New Drugs for Bad Bugs", COMBACTE, TRANSLOCATION, Drive AB or ENABLE, to harness the power of collaboration; furthermore encourages public-private partnerships aiming to foster innovation in the field;
Amendment 65 #
Draft opinion
Paragraph 3
Paragraph 3
3. Expresses the urgent need to foster partnerships throughout the EUwithin the EU and beyond in order to enhance the exchange of best practices and improve knowledge on AMR;
Amendment 72 #
Draft opinion
Paragraph 4
Paragraph 4
4. Stresses the need to improve data collection on prevalence, patterns and us/misuse on a systemic levelmanner throughout the EU, and to monitor and act rapidly on AMR-related trends and developments; points out the added value of eHealth and digitalisation, which offer the opportunity to pool and cumulate data on AMR;
Amendment 83 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls for the strengthening AMR surveillance national systems in developing countries in order to achieve the standardization of results;
Amendment 89 #
Draft opinion
Paragraph 5 b (new)
Paragraph 5 b (new)
5b. Stresses the importance of closer cooperation between industry and the university and scientific establishment, so as to facilitate the creation of dedicated structures within universities and scientific centres for the purpose of fighting against AMR;